Cohen Capital Management Inc. raised its stake in shares of Zimmer Biomet Holdings Inc. (NYSE:ZBH) by 2.2% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 80,730 shares of the company’s stock after buying an additional 1,750 shares during the period. Zimmer Biomet Holdings accounts for approximately 2.9% of Cohen Capital Management Inc.’s portfolio, making the stock its 6th largest position. Cohen Capital Management Inc.’s holdings in Zimmer Biomet Holdings were worth $10,497,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Commerce Bank boosted its position in shares of Zimmer Biomet Holdings by 547.5% in the second quarter. Commerce Bank now owns 185,086 shares of the company’s stock valued at $22,281,000 after buying an additional 156,501 shares in the last quarter. Atalanta Sosnoff Capital LLC bought a new position in Zimmer Biomet Holdings during the second quarter valued at $42,984,000. Retirement Systems of Alabama increased its position in Zimmer Biomet Holdings by 9.0% in the second quarter. Retirement Systems of Alabama now owns 99,636 shares of the company’s stock valued at $11,994,000 after buying an additional 8,258 shares during the last quarter. California State Teachers Retirement System increased its position in Zimmer Biomet Holdings by 6.6% in the second quarter. California State Teachers Retirement System now owns 396,264 shares of the company’s stock valued at $47,702,000 after buying an additional 24,592 shares during the last quarter. Finally, Eqis Capital Management Inc. increased its position in Zimmer Biomet Holdings by 11.8% in the second quarter. Eqis Capital Management Inc. now owns 11,216 shares of the company’s stock valued at $1,350,000 after buying an additional 1,181 shares during the last quarter. 85.05% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Shares of Zimmer Biomet Holdings Inc. (NYSE:ZBH) traded down 0.37% during mid-day trading on Monday, reaching $101.98. The company had a trading volume of 1,586,694 shares. Zimmer Biomet Holdings Inc. has a 52-week low of $88.27 and a 52-week high of $133.21. The company’s 50-day moving average price is $113.16 and its 200-day moving average price is $121.67. The company has a market capitalization of $20.43 billion, a PE ratio of 57.10 and a beta of 1.28.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings results on Monday, October 31st. The company reported $1.79 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $1.79. Zimmer Biomet Holdings had a net margin of 3.46% and a return on equity of 16.48%. The business had revenue of $1.83 billion for the quarter, compared to the consensus estimate of $950.20 million. During the same period in the prior year, the business posted $1.64 earnings per share. Zimmer Biomet Holdings’s revenue for the quarter was up 4.0% compared to the same quarter last year. On average, analysts forecast that Zimmer Biomet Holdings Inc. will post $7.92 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The legal version of this story can be read at https://www.thecerbatgem.com/2016/11/28/zimmer-biomet-holdings-inc-zbh-shares-bought-by-cohen-capital-management-inc.html.

Several equities analysts have weighed in on ZBH shares. Jefferies Group reissued a “buy” rating and set a $150.00 price target on shares of Zimmer Biomet Holdings in a research report on Monday, August 8th. SunTrust Banks Inc. started coverage on Zimmer Biomet Holdings in a research report on Thursday, August 11th. They set a “buy” rating and a $155.00 price target for the company. Barclays PLC raised their price target on Zimmer Biomet Holdings from $140.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 23rd. RBC Capital Markets set a $143.00 price target on Zimmer Biomet Holdings and gave the stock a “buy” rating in a research report on Wednesday, September 14th. Finally, Argus reissued a “buy” rating and set a $140.00 price target on shares of Zimmer Biomet Holdings in a research report on Thursday, September 22nd. One analyst has rated the stock with a sell rating, three have given a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $131.15.

In other news, insider Daniel E. Williamson sold 2,716 shares of the company’s stock in a transaction on Thursday, September 8th. The shares were sold at an average price of $129.96, for a total value of $352,971.36. Following the transaction, the insider now directly owns 2,000 shares of the company’s stock, valued at $259,920. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.22% of the stock is currently owned by insiders.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

5 Day Chart for NYSE:ZBH

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.